Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required regulatory approvals to import and sell Profound’s two advanced ablative technologies in Saudi Arabia are already in place TORONTO and RIYADH, Saudi Arabia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that de ...

MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior yea ...

Founded in 1949 in Minneapolis, MN, Medtronic plc ( MDT ) is an American-Irish medical device and components company. After its acquisition of Covidien in 2015, the company moved its legal and executive headquarters to Dublin, butI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the ...

Founded in 1949 in Minneapolis, MN, Medtronic plc ( MDT ) is an American-Irish medical device and components company. After its acquisition of Covidien in 2015, the company moved its legal and executive headquarters to Dublin, butI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the ...

政府停摆结束与市场影响 - 美国参议院批准了一项两党法案以结束长达41天的政府停摆这是美国历史上最长的一次停摆[1] - 尽管众议院休会可能导致最终批准延迟但总统特朗普支持重启政府这些关键措施提振了华尔街市场[1] 动量投资策略 - 推荐使用Driehaus策略即“买高卖更高”的投资方法这是一种成熟的投资策略[2] - 该策略的核心观点是宁愿投资价格正在上涨的股票并承担其可能开始下跌的风险也不投资已处于下跌中的股票[3] - 美国个人投资者协会将50日移动平均线百分比作为构建Driehaus投资组合的关键标准之一[3] - 50日移动平均线百分比的计算公式为（月末价格减去月末价格的50日移动平均值）除以月末价格的50日移动平均值[4] - 该策略还包含另一个动量指标——正相对强度正百分比50日移动平均线表明股票交易价格高于其50日移动平均线暗示处于上升趋势[4] - Driehaus策略主要关注强劲的盈利增长率和令人印象深刻的盈利预测以挑选潜在表现优异者[5] - 具有强劲盈利超预期历史的公司在该策略中也受到重视旨在提供更好的长期回报[5] 股票筛选参数 - 筛选参数要求股票必须具有Zacks排名第一和动量评分为A或B[6] - 研究表明具有A或B风格评分且结合Zacks排名第一或第二的股票提供最佳上涨潜力[6] - Zacks排名第一的股票无论市场好坏都有经过验证的跑赢历史[7] - 筛选标准包括过去5年平均每股收益增长率高于2%以确保业务持续改善[8] - 要求过去12个月每股收益增长率为正且高于行业中位数表明盈利表现优于行业[8] - 过去四个季度平均每股收益惊喜大于5%稳健的盈利惊喜历史预示着更好的价格表现[8] - 要求50日移动平均线百分比变化为正且相对强度超过4周表明处于上升趋势[9] - 动量评分需等于或优于B表明这是利用动量取得成功概率最高的理想选择[9] - 上述参数将超过7,743只股票的范围缩小至仅13只[9] 推荐动量股票 - Insulet Corporation在全球范围内开发、制造和销售胰岛素输送系统其动量评分为A过去四个季度平均盈利惊喜为17.8%[10] - Celestica Inc及其子公司在全球提供供应链解决方案其动量评分为A过去四个季度平均盈利惊喜为6.9%[11] - Innodata Inc是一家在美国、英国、荷兰、加拿大及全球运营的数据工程公司其动量评分为A过去四个季度平均盈利惊喜为55.9%[12]

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstratin ...

Question-and-Answer SessionKevin CaliendoUBS Investment Bank, Research Division Okay. Sounds good. The third quarter, you highlighted strong growth in EMEA, APAC, Lat Am in the Clear Aligner volumes, in particular. I really want to unpack that a little bit. Were you -- is this being driven -- there's a lot of variables that can drive your growth? It could be new doctors that you're signing up. It can be utilization going higher, it could be new products that you've launched. And I think you mentioned all 3 ...

Orthofix Medical (NasdaqGS:OFIX) 2025 Conference November 11, 2025 01:15 PM ET Speaker0Right. Good afternoon, everyone. Thank you for joining us. I'm Danielle Leontofsky. I'm the U.S. MedTech analyst here at UBS. Very honored to have with us Orthofix Medical. We have President and CEO Massimo Calafiore. We have—well, no, we do not have the Chief Financial Officer. I was reading off that. We have Julie Dewey, Head of Investor Relations. Unfortunately, Julie Andrews, Chief Financial Officer, could not make it ...

期权交易活动 - 监测到8笔大额期权交易 其中看跌期权2笔 总金额370,845美元 看涨期权6笔 总金额506,319美元 [1] - 在已识别的交易中 25%的投资者以看涨预期开仓 62%的投资者以看跌预期开仓 整体呈现明显看跌倾向 [1] - 主要市场参与者过去三个月的关注价格区间为40美元至70美元 [2] 重大期权交易详情 - 一笔最大的看跌期权为扫单交易 行权价65美元 到期日2025年12月19日 总交易金额339,600美元 [8] - 一笔最大的看涨期权为扫单交易 行权价65美元 到期日2026年3月20日 总交易金额195,600美元 [8] - 另一笔看涨期权为普通交易 行权价70美元 到期日2028年1月21日 总交易金额192,400美元 [8] 公司业务与市场表现 - 公司致力于为糖尿病患者设计并商业化连续血糖监测系统 其系统正演进至与胰岛素泵集成以实现自动胰岛素输送 [9] - 公司股票当前价格为57.71美元 日内上涨5.23% 成交量为4,834,034股 RSI指标暗示股票可能接近超卖区域 [13] - 下一次财报预计在93天后发布 [13] 分析师观点与目标价 - 过去一个月内有5位行业分析师给出见解 平均目标价为84.0美元 [10] - 花旗分析师维持买入评级 目标价75美元 BTIG分析师维持买入评级 目标价85美元 瑞银分析师维持买入评级 目标价95美元 [11] - 巴克莱分析师维持持股观望评级 目标价80美元 加拿大皇家银行资本市场分析师维持跑赢大市评级 目标价85美元 [11]

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Company: Baxter International, Inc. (NYSE: BAX) is a global company that develops, manufactures, and markets medical products used in hospitals and other healthcare facilities. Class Period: February 23, 2022 and July 30, 2025 The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of certain investors who purchased or otherwise acquired Baxter International, Inc. because the Company allegedly mislead investors regarding the safety of ...